138 related articles for article (PubMed ID: 9181232)
21. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.
Arrieta O; Michel Ortega RM; Angeles-Sánchez J; Villarreal-Garza C; Avilés-Salas A; Chanona-Vilchis JG; Aréchaga-Ocampo E; Luévano-González A; Jiménez MA; Aguilar JL
J Exp Clin Cancer Res; 2009 Aug; 28(1):120. PubMed ID: 19709439
[TBL] [Abstract][Full Text] [Related]
22. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
Swanson DA
Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
[No Abstract] [Full Text] [Related]
23. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA).
Klepp O; Flodgren P; Maartman-Moe H; Lindholm CE; Unsgaard B; Teigum H; Fosså SD; Paus E
Ann Oncol; 1990 Jul; 1(4):281-8. PubMed ID: 1702312
[TBL] [Abstract][Full Text] [Related]
24. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.
Eastham JA; Wilson TG; Russell C; Ahlering TE; Skinner DG
Urology; 1994 Jan; 43(1):74-80. PubMed ID: 7506856
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
26. Localization of alpha-fetoprotein and human chorionic gonadotropin to specific histologic types of nonseminomatous testicular cancer.
Fowler JE; Sesterhenn I; Stutzman RE; Mostofi FK
Urology; 1983 Dec; 22(6):649-54. PubMed ID: 6196899
[TBL] [Abstract][Full Text] [Related]
27. Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer.
Bosl GJ; Lange PH; Fraley EE; Goldman A; Nochomovitz LE; Rosai J; Waldmann TA; Johnson K; Kennedy BJ
Cancer; 1981 Jan; 47(2):328-32. PubMed ID: 6161691
[TBL] [Abstract][Full Text] [Related]
28. Tumor markers at the time of recurrence in patients with germ cell tumors.
Trigo JM; Tabernero JM; Paz-Ares L; García-Llano JL; Mora J; Lianes P; Esteban E; Salazar R; López-López JJ; Cortés-Funes H
Cancer; 2000 Jan; 88(1):162-8. PubMed ID: 10618619
[TBL] [Abstract][Full Text] [Related]
29. Detection of vital germ cell tumor cells in short-term cell cultures of primary tumors and of retroperitoneal metastasis--clinical implications.
Otto T; Virchow S; Fuhrmann C; Steinberg F; Streffer C; Goepel M; Rübben H
Urol Res; 1997; 25(2):121-4. PubMed ID: 9144879
[TBL] [Abstract][Full Text] [Related]
30. [Biological markers and germinal tumors of the testis. Value and limitations of the assay of chorionic gonadotrophin hormone and alpha-fetoprotein].
Bassoulet J; Pabot du Chatelard P; Ricordel I; Auberget JL; Guillemot MC; Merrer J; Timbal Y
J Urol (Paris); 1988; 94(8):393-6. PubMed ID: 2467947
[TBL] [Abstract][Full Text] [Related]
31. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
32. Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer.
Javadpour N; McIntire KR; Waldmann TA
Natl Cancer Inst Monogr; 1978 Dec; (49):209-13. PubMed ID: 86162
[TBL] [Abstract][Full Text] [Related]
33. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
34. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
35. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance.
Thompson PI; Nixon J; Harvey VJ
J Clin Oncol; 1988 Oct; 6(10):1597-603. PubMed ID: 2459319
[TBL] [Abstract][Full Text] [Related]
36. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study.
Weissbach L; Bussar-Maatz R; Mann K
Eur Urol; 1997; 32(1):16-22. PubMed ID: 9266226
[TBL] [Abstract][Full Text] [Related]
37. Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review.
Chakiryan NH; Dahmen A; Cucchiara V; Briganti A; Montorsi F; Salonia A; Spiess PE; Necchi A
J Urol; 2021 Jun; 205(6):1569-1576. PubMed ID: 33617328
[TBL] [Abstract][Full Text] [Related]
38. A 10-year retrospective single-center study of alpha-fetoprotein and beta-human chorionic gonadotropin in Romanian children with (para)gonadal tumors and cysts.
Ataikiru UO; Iacob ER; Miron I; Popoiu CM; Boia ES
J Pediatr Endocrinol Metab; 2022 Mar; 35(3):363-371. PubMed ID: 34968016
[TBL] [Abstract][Full Text] [Related]
39. Serum AFP, hCG and CEA in the management of patients with testicular, ovarian and extragonadal germ cell tumors.
Motawy MS; Szymendera JJ; al-Jazzaf H; Behbehani AE; Foudeh MO; Ebraheem AK; Nasralla MY; Ali MA
Int J Biol Markers; 1992; 7(2):80-6. PubMed ID: 1378875
[TBL] [Abstract][Full Text] [Related]
40. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases.
Nazeer T; Ro JY; Amato RJ; Park YW; Ordonez NG; Ayala AG
Oncol Rep; 1998; 5(6):1425-9. PubMed ID: 9769381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
